UB Paderborn / Katalog / Suche / in CDI

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

The lancet oncology, 2014-11, Vol.15 (12), p.1397-1406

2014

Link zum Volltext

Verfügbarkeit prüfen

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

British journal of cancer, 2020-03, Vol.122 (7), p.971-977

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease

Breast cancer research and treatment, 2014-06, Vol.145 (2), p.411-418

2014

Link zum Volltext

Verfügbarkeit prüfen

Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer

Health physics (1958), 2014-04, Vol.106 (4), p.494

2014

Link zum Volltext

Verfügbarkeit prüfen

Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases

Nuclear medicine communications, 2012-07, Vol.33 (7), p.726-732

2012

Link zum Volltext

Verfügbarkeit prüfen

Exercise‐induced overexpression of key regulatory proteins involved in glucose uptake and metabolism in tetraplegic persons: molecular mechanism for improved glucose homeostasis

The FASEB journal, 1998-12, Vol.12 (15), p.1701-1712

1998

Link zum Volltext

Verfügbarkeit prüfen

Improved body composition after 8 wk of electrically stimulated leg cycling in tetraplegic patients

American journal of physiology. Regulatory, integrative and comparative physiology, 1997-09, Vol.273 (3), p.1072-R1079

1997

Link zum Volltext

Verfügbarkeit prüfen

Enhanced Detection of Blood Flow in the Normal Canine Prostate Using an Ultrasound Contrast Agent

Investigative radiology, 2000-02, Vol.35 (2), p.118-118

2000

Link zum Volltext

Verfügbarkeit prüfen

850 First experience with intra-abdominal 224radium-labelled microparticles (radspherin) after cytoreductive surgery for peritoneal metastasis in recurrent epithelial ovarian cancer (phase 1 study)

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A27-A28

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II trial of TG01/GM-CSF and gemcitabine as adjuvant therapy for treating patients with resected RAS-mutant adenocarcinoma of the pancreas

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4119-4119

2017

Link zum Volltext

Verfügbarkeit prüfen

Contrast-enhanced power Doppler imaging of normal and decreased blood flow in canine prostates

Ultrasound in medicine & biology, 2001-07, Vol.27 (7), p.909-913

2001

Link zum Volltext

Verfügbarkeit prüfen

Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.5038-5038

2013

Link zum Volltext

Verfügbarkeit prüfen

Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.19-19

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC)

Cancer immunology research, 2019-02, Vol.7 (2_Supplement), p.A022-A022

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS4694-TPS4694

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.5021-5021

2013

Link zum Volltext

Verfügbarkeit prüfen

A bone marrow toxicity model for 223Ra alpha-emitter radiopharmaceutical therapy

Physics in medicine & biology, 2012-05, Vol.57 (10), p.3207-3222

2012

Link zum Volltext

Verfügbarkeit prüfen

A bone marrow toxicity model for super(223)Ra alpha-emitter radiopharmaceutical therapy

Physics in medicine & biology, 2012-05, Vol.57 (10), p.3207-3222

2012

Link zum Volltext

Verfügbarkeit prüfen

A bone marrow toxicity model for 223 Ra alpha-emitter radiopharmaceutical therapy

Physics in medicine & biology, 2012-05, Vol.57 (10), p.3207-3222

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I pharmacokinetic and biodistribution study with escalating doses of ^sup 223^Ra-dichloride in men with castration-resistant metastatic prostate cancer

European journal of nuclear medicine and molecular imaging, 2013-09, Vol.40 (9), p.1384

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I pharmacokinetic and biodistribution study with escalating doses of super(223)Ra-dichloride in men with castration-resistant metastatic prostate cancer

European journal of nuclear medicine and molecular imaging, 2013-09, Vol.40 (9), p.1384-1393

2013

Link zum Volltext

Verfügbarkeit prüfen

Ultrasonography of the prostate

The Journal of the Acoustical Society of America, 2003, Vol.113 (2), p.694

Aksnes, Anne Kirsti

2003

Link zum Volltext

Verfügbarkeit prüfen

Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

European journal of nuclear medicine and molecular imaging, 2013-09, Vol.40 (9), p.1384-1393

2013

Link zum Volltext

Verfügbarkeit prüfen

18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)

EJNMMI research, 2011-06, Vol.1 (1), p.4-4

2011

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease

Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer

Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases

Exercise‐induced overexpression of key regulatory proteins involved in glucose uptake and metabolism in tetraplegic persons: molecular mechanism for improved glucose homeostasis

Improved body composition after 8 wk of electrically stimulated leg cycling in tetraplegic patients

Enhanced Detection of Blood Flow in the Normal Canine Prostate Using an Ultrasound Contrast Agent

850 First experience with intra-abdominal 224radium-labelled microparticles (radspherin) after cytoreductive surgery for peritoneal metastasis in recurrent epithelial ovarian cancer (phase 1 study)

A phase I/II trial of TG01/GM-CSF and gemcitabine as adjuvant therapy for treating patients with resected RAS-mutant adenocarcinoma of the pancreas

Contrast-enhanced power Doppler imaging of normal and decreased blood flow in canine prostates

Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases

Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases

Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial

Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC)

A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases

Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study

A bone marrow toxicity model for 223Ra alpha-emitter radiopharmaceutical therapy

A bone marrow toxicity model for super(223)Ra alpha-emitter radiopharmaceutical therapy

A bone marrow toxicity model for 223 Ra alpha-emitter radiopharmaceutical therapy

Phase I pharmacokinetic and biodistribution study with escalating doses of ^sup 223^Ra-dichloride in men with castration-resistant metastatic prostate cancer

Phase I pharmacokinetic and biodistribution study with escalating doses of super(223)Ra-dichloride in men with castration-resistant metastatic prostate cancer

Ultrasonography of the prostate

Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)

Suchergebnisse filtern